A general, highly enantioselective Michael addition of nitroalkanes to α,β-unsaturated enones catalyzed by 9-amino(9-deoxy)-epi-quinine: a remarkable additive effect
作者:Siyang Liu、Qingqing Wang、Ling Ye、Zhichuan Shi、Zhigang Zhao、Xuejun Yang、Keyi Ding、Xuefeng Li
DOI:10.1016/j.tet.2016.07.008
日期:2016.8
A particularly general protocol for the organocatalytic asymmetric Michael addition of nitroalkanes to α,β-unsaturated enones is reported. The Michaelreaction proceeded smoothly and provided the desired adducts in moderate to excellent yields (55–99%) and good to excellent enantioselectivities (65–99% ee). The addition of readily available achiral base significantly enhanced the reactivity without
Kinetic Resolution of Aminoalkenes by Asymmetric Hydroamination: A Mechanistic Study
作者:Alexanderâ L. Reznichenko、Frank Hampel、Kaiâ C. Hultzsch
DOI:10.1002/chem.200902229
日期:2009.11.23
complex for 1‐alkylaminopentenes diminishes resolution efficiency. Nevertheless, the relative cyclization rate for the two diastereomeric substrate–catalyst complexes remains in a typical range of 7–10:1. Plausible attractive π interactions between the aryl substituent and either the metal center or the aromatic system of the bis(triarylsilyl)‐substituted binaphtholate ligand may explain increased stability
HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR
申请人:Grandel Roland
公开号:US20090306175A1
公开(公告)日:2009-12-10
The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT
6
receptor ligand.
Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
申请人:Grandel Roland
公开号:US08642642B2
公开(公告)日:2014-02-04
The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT6 receptor ligand.